サインイン 無料でサインアップします。

ProMIS Neurosciencesの収益YQ/Q

ProMIS Neurosciencesの収益YQ/Qは何ですか。

ProMIS Neurosciences, Inc.の収益YQ/Qは2,276.58%です。

収益YQ/Qの定義は何ですか。

四半期収益成長率、前年比は、前年同期の業績と比較して、売上高の増加率がパーセンテージとして表されています。

Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.

OTCのセクタHealth Careにおける収益YQ/Qの企業と比べるProMIS Neurosciences

ProMIS Neurosciencesは何をしますか。

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

ProMIS Neurosciencesと類似の収益yq/q